Compare BIXI & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIXI | TTRX |
|---|---|---|
| Founded | 2025 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.6M | 285.1M |
| IPO Year | 2025 | 2025 |
| Metric | BIXI | TTRX |
|---|---|---|
| Price | $10.09 | $9.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 24.7K | ★ 46.1K |
| Earning Date | 01-01-0001 | 05-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.80 | $2.57 |
| 52 Week High | $10.15 | $11.69 |
| Indicator | BIXI | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 69.61 | 58.30 |
| Support Level | $9.89 | $2.81 |
| Resistance Level | $10.15 | $10.72 |
| Average True Range (ATR) | 0.02 | 0.62 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 50.41 | 55.41 |
Bitcoin Infrastructure Acquisition Corp Ltd is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.